References

  1. Estragyn Vaginal Cream Product Monograph. Searchlight Pharma Inc. August 17, 2016.
  2. D. W. Sturdee and N. Panay, on behalf of the International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;(13):509-522.
  3. Frank SM et al. Vaginal Health: Insights, Views & Attitudes (VIVA) survey – Canadian cohort, Menopause International, March 2013;(19):20–27.
  4. Official Mark of the Régie de l’assurance maladie du Québec; List of Medications, Last Updated on 10 July 2019. Available at http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/liste_med/2019/liste_med_2019_07_10_en.pdf. Accessed July 29, 2019.
  5. Confidential Searchlight Pharma documentation.
  6. Health Canada. Estragyn Vaginal Cream Product Information.
  7. Data on file. Searchlight Pharma.
  8. The Society of Obstetricians and Gynaecologists of Canada. SOGC Clinical Practice Guideline, No. 311. September 2014.
  9. Non-insured Health Benefits-Drug Benefit List 2019. Available at https://www.canada.ca/content/dam/isc-sac/documents/services/reports-publications/nihb/drug-benefit-list/dbl-2019-eng.pdf . Accessed on August 6, 2019.
  10. Formulary Nova Scotia, July 2019. Available at https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf. Accessed on August 6, 2019.
  11. The North American Menopause Society. Position statement. The 2019 hormone therapy position statement of The North American Menopause Society. Menopause, 2017. Available at http://www.menopause.org/docs/default-source/2017/nams-2017-hormone-therapy-position-statement.pdf. Accessed on July 14, 2017.